...Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to... ...is also in Phase III testing as first-line treatment of pancreatic cancer.
Elizabeth S. Eaton
AAV-XLRPGR
AAV2-REP1
Acelarin
DCC-2618
Nightstar Therapeutics Ltd.
NightstaRx Ltd.
NuCana...
...Phase I/II trial to evaluate single subretinal injections of AAV-XLRPGR in about 24 male patients. NightstaRx Ltd.... ...RPGR) gene Indication Treat X-linked retinitis pigmentosa Endpoint: Safety Status: Phase I/II started Milestone: NA
Julian Zhu
AAV-XLRPGR
NightstaRx Ltd.
Retinitis...
...has disclosed investments in seven European companies: Adaptimmune Therapeutics plc , CRISPR Therapeutics AG , NightstaRx Ltd.... ...In NightstaRx case, a U.S. investor pushed the company to think bigger. According to Mott, NightstaRx... ...with this platform?" NEA led a $35 million series B round in November. In parallel, NightstaRx...
...Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to... ...is also in Phase III testing as first-line treatment of pancreatic cancer.
Elizabeth S. Eaton
AAV-XLRPGR
AAV2-REP1
Acelarin
DCC-2618
Nightstar Therapeutics Ltd.
NightstaRx Ltd.
NuCana...
...Phase I/II trial to evaluate single subretinal injections of AAV-XLRPGR in about 24 male patients. NightstaRx Ltd.... ...RPGR) gene Indication Treat X-linked retinitis pigmentosa Endpoint: Safety Status: Phase I/II started Milestone: NA
Julian Zhu
AAV-XLRPGR
NightstaRx Ltd.
Retinitis...
...has disclosed investments in seven European companies: Adaptimmune Therapeutics plc , CRISPR Therapeutics AG , NightstaRx Ltd.... ...In NightstaRx case, a U.S. investor pushed the company to think bigger. According to Mott, NightstaRx... ...with this platform?" NEA led a $35 million series B round in November. In parallel, NightstaRx...